Incyte Corp (NASDAQ:INCY)
| 79.62 Delayed Data As of Nov 30 |  +1.83 / +2.35%Today’s Change | 63.40 Today|||52-Week Range 84.86 | +8.47% Year-to-Date |
Latest INCY News | Press Releases
| Incyte (INCY) Outperforms YTD: Will the Momentum Continue? Nov 25 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 77.79 |
| Today’s open | 77.81 |
| Day’s range | 77.58 - 79.67 |
| Volume | 72,013 |
| Average volume (3 months) | 1,346,674 |
| Market cap | $17.4B |
Data as of 4:01pm ET, 11/30/2022
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -58.39% |
| Earnings growth (next 5 years) | +36.00% |
| Revenue growth (last year) | +11.98% |
| P/E ratio | 20.2 |
| Price/Sales | 5.46 |
| Price/Book | 4.59 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VTRSViatris Inc | -0.15 | -1.34% |
| SGENSeagen Inc | +4.02 | +3.43% |
| UTHRUnited Therapeutics ... | +8.65 | +3.19% |
| HZNPHorizon Therapeutics... | +21.51 | +27.30% |
Data as of 4:01pm ET, 11/30/2022
Financials
| Next reporting date | February 16, 2023 |
| EPS forecast (this quarter) | $0.31 |
| Annual revenue (last year) | $3.0B |
| Annual profit (last year) | $948.6M |
| Net profit margin | 31.76% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Wilmington, Delaware |
Forecasts
